Predicting clinical response to everolimus in ER+ breast cancers using machine-learning

Aritro Nath1*, Patrick A. Cosgrove1, Jeffrey T. Chang2 and Andrea H. Bild1*

1City of Hope Comprehensive Cancer Center, Department of Medical Oncology and Therapeutics, Monrovia, CA, United States, 2Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, TX, United States

Endocrine therapy remains the primary treatment choice for ER+ breast cancers. However, most advanced ER+ breast cancers ultimately develop resistance to endocrine. This acquired resistance to endocrine therapy is often driven by the activation of the PI3K/AKT/mTOR signaling pathway. Everolimus, a drug that targets and inhibits the mTOR complex has been shown to improve clinical outcomes in metastatic ER+ breast cancers. However, there are no biomarkers currently available to guide the use of everolimus in the clinic for progressive patients, where multiple therapeutic options are available. Here, we utilized gene expression signatures from 9 ER+ breast cancer cell lines and 23 patients treated with everolimus to develop and validate an integrative machine learning biomarker of mTOR inhibitor response. Our results show that the machine learning biomarker can successfully distinguish responders from non-responders and can be applied to identify patients that will most likely benefit from everolimus treatment.

KEYWORDS machine-learning, biomarker, everolimus, estrogen receptor positive breast cancer, prognostic model, random forest, feature selection

Introduction

Breast cancer is now the most commonly diagnosed malignancy and cause of cancer-related death in women worldwide (Houghton and Hankinson, 2021). In the United States, one in eight women will be diagnosed with breast cancer throughout their lifetime (Siegel et al., 2019). At the molecular level, nearly 3 in 4 breast cancers display increased expression of the estrogen receptor (ER+) and do not express the human epidermal growth factor receptor 2 (HER2-). The primary systemic treatment of ER+/HER2- breast cancer is endocrine therapy, which targets the dependency of these tumors on the estrogen signaling pathway for proliferation. These include selective estrogen receptor modulators (SERMs) like tamoxifen, selective estrogen receptor degraders (SERDs) like fulvestrant, and aromatase inhibitors (AIs) like exemestane (Smith and Dowsett, 2003; Patel and Bihani, 2018).

Patients with primary or early-stage ER+/HER2- breast cancer generally have a favorable outlook, with excellent 5-year survival rates on endocrine therapy, even without
the use of adjuvant chemotherapy (Early Breast Cancer Trialists' Collaborative et al., 2012). However, the response rates tend to be lower in patients displaying tumor regression on endocrine therapy (Osborne and Schiff, 2011). This outcome has been attributed to primary or acquired endocrine resistance in progressive tumors. Studies have shown that advanced and metastatic ER+ breast cancers can develop endocrine resistance through various mechanisms, such as mutations in the ER-alpha gene, amplification/overexpression of epidermal growth factor and fibroblast growth factor receptor family genes, and activation of downstream signaling via the PI3K/AKT/mTOR signaling pathway (Musgrove and Sutherland, 2009; Clarke et al., 2015). Consequently, add-on drugs that target the resistance mechanisms, such as the PI3K inhibitor alpelisib and the mTOR inhibitor everolimus, have shown promising results in clinical trials for advanced ER+ breast cancers. For example, the SOLAR-1 trial reported an improvement of median overall survival in PI3KCA mutated cancers from 5.7 months in the fulvestrant group to 11 months in the alpelisib plus fulvestrant group. The BOLERO-2 trial showed significant improvement in progression-free survival in post-menopausal ER+ breast cancers from 2.8 months on exemestane alone to 6.9 months on everolimus plus exemestane (Baselga et al., 2012).

Unlike the PI3K inhibitors, currently, there are no clinically relevant biomarkers available for the selection of everolimus as the treatment for ER+ breast cancers. In the absence of suitable guidelines, this choice is primarily based on patient and caregiver preferences. We have previously shown that effective prognostic and response biomarkers can be developed from the baseline (pre-treatment) transcriptomes of the tumors using systems biology and machine learning (Nath et al., 2019; Nath et al., 2022). In this study, we apply a machine learning framework to develop a novel biomarker model to predict clinical response to everolimus. We adopt a hybrid approach that integrates signatures of treatment response from well-controlled in vitro experimentation of cell lines treated with everolimus with empirical signatures derived from the baseline tumor transcriptomes of 23 patients. Using this approach, we develop and validate a predictive model of everolimus response and demonstrate its potential application in identifying candidates for mTOR inhibitor treatment.

Materials and methods

Breast cancer cell line culture and drug treatment

Nine ER+/HER2- breast cancer cell lines were used in this study. CAMA-1, LY2, and MCF7 cell lines were grown and cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Cat# 11995073) + 10% heat-inactivated Fetal Bovine Serum (PBS, Sigma-Aldrich, Cat # F4135) + 1x antibiotic-antimycotic (Gibco, Cat# 15240062). T47D, BT-483, ZR-75-1, HCC1428, MDA-MB-134-VI, and MDA-MB-175-VII were grown and cultured in RPMI-1640 (Gibco, Cat# 11875119) + 10% heat-inactivated FBS + 1x antibiotic-antimycotic. Cell lines were authenticated by STR profiling (at City of Hope Integrative Genomics Core) and tested negative for mycoplasma contamination using MycoAlert Mycoplasma Detection Kit (Lonza, Cat# LT07-118).

To determine an effective concentration of everolimus and exemestane for everolimus plus exemestane signature each cell line was plated at 1,000 cell/well in a 384-well flat bottom TC-treated plate (Corning, Cat# 3764) and allowed to adhere at 37°C humidified incubator + 5% CO2. After 24hrs post-plating, cells were incubated with a dose-response of everolimus or exemestane or 0.2% DMSO control for 4 days (40 μL total volume). Viability was assessed as a measure of total ATP using the CellTiter-Glo assay (Promega, Cat# G7573) according to manufacturer instructions. See Supplementary Table S1 and Supplementary Figure S1.

Each cell line was plated at 250,000 cells/well in 2 ml of the respective culture media on a 6-well tissue culture treated plate (Costar, Cat# 3506) and allowed to adhere at 37°C humidified incubator + 5% CO2. After 24 h post-plating, the cells were treated with either 0.2% DMSO (control) or a combination of 0.5 nM everolimus + 25 μM exemestane (Selleck Chemicals, Cat# S1120, S1196 respectively) in their respective culture media. Following treatment, the cells were incubated for 6 h at 37°C + 5% CO2 in a humidified incubator.

Cell lines RNA-seq data preprocessing

After 6 h of treatment, the plated cells were rinsed one time with ice-cold 1x PBS (Gibco, Cat# 10010049) followed by collection via cell scrapping in ice-cold 1x PBS. Collected cells were stored frozen overnight at -80°C in RNAlater (Invitrogen, Cat# AM7023). Frozen cells were thawed at 4°C, washed in 1x PBS, and RNA was isolated using the AllPrep DNA/RNA Mini Kit (Qiagen, Cat# 80204) according to the manufacturer’s instructions. Sequencing libraries were prepared and ran at Fulgent Genetics (Temple City, CA) using NEBNext Ultra II Directional RNA Library Prep Kit (New England Biolabs, Cat# E7760L) and sequenced on Illumina NovaSeq 6000 with S4 flow cell (2 × 150 cycles) with 20 M PE reads per sample.
adapter trimming was performed using trimmomatic (0.33) (Bolger et al., 2014). Sequences were aligned using STAR (2.7.6a) (Dobin et al., 2013), followed by counts estimation using HTSeq (Anders et al., 2015) and estimation of gene expression levels using RSEM (1.3.1) (Li and Dewey, 2011). Transcript per million (TPM) values from RSEM were log2(x+1) transformed and filtered to remove genes with the lowest variance (25th percentile) and lowest expression (30th percentile).

Developing signature for *in vitro* everolimus response using bayesian binary regression

Filtered TPM matrix for the nine cell lines was used to train a supervised Bayesian binary regression model based on the method developed by West et al. (West et al., 2001) and implemented in the GenePattern module SIGNATURE (Chang et al., 2011). Expression values were quantile normalized and a set of 100 features (genes) were obtained that were correlated with the treatment status (DMSO vs. everolimus plus exemestane). A prediction model based on Bayesian regression that used the two metagenes (principal component of the signature gene matrix) with Monte-Carlo simulations was used to obtain classification accuracy in leave-one-out cross-validation (LOOCV) analysis. Based on the successful classification of the cell lines using this model, the selected features were used for further analysis.

Patient microarray data preprocessing

Gene expression data from patients in a neoadjuvant everolimus trial (Sabine et al., 2010) were obtained from NCBI GEO accession GSE119262. We used expression data from the pre-treatment tumors to train and validated the model. The tumor samples were profiled using Illumina HumanRef-8 v2 Expression BeadChips and quantile normalized using BeadArray (Sabine et al., 2010). We aggregated the expression matrix by first averaging data from multiple probes at the gene level and then averaging the expression levels of replicates. The log-transformed expression levels were standardized such that each gene had a mean = 0 and standard deviation = 1 across the samples.

Integrative machine-learning framework for response prediction

We implemented a LOOCV framework using the caret package for R (Kuhn, 2021) to combine the *in vitro* signature genes with genes selected from the clinical dataset to develop an integrative biomarker. In each iteration of the cross-validation, we first selected a set of relevant features using Fast Correlation Based Filter for Feature Selection implemented (FCBF) using the FCBF package for R (Lubiana and Nakaya, 2021). We then obtained an integrative signature by combining the *in vitro* signature and the FCBF selected features and used this set of genes as predictors in a random forest model, with the patient response as the outcome variable. This was performed using the randomForest R package (Liaw and Wiener, 2002). An internal cross-validation was performed within each iteration to tune the mtry hyperparameter. All analyses were performed in R version 4.1.0 (R Core Team, 2021).

Functional enrichment analyses

Pathway enrichment analyses were performed using the g:Profiler2 package for R (Kolberg et al., 2020). Genes in the *in vitro* signature were split into two lists (up or down in everolimus treated cells) and analyzed for enrichment of GO:BP, KEGG, and REACTOME pathway terms. Functional enrichment was performed for the over-representation of genes using the hypergeometric test and adjusted for multiple comparisons. Enrichment plots and tables were created using the g:Profiler2 package, with color coding in the tables showing the level of evidence associated with the terms. A dark blue color indicated weaker evidence whereas an orange color indicated strong, experimentally derived evidence for the term.

Results

An integrative machine learning framework

We developed an integrated biomarker development approach that harnessed evidence from controlled *in vitro* experiments with ER+/HER2- breast cancer cell lines treated with everolimus and combined this with data from a neoadjuvant clinical trial of ER+ breast cancer patients treated with everolimus. The outline for our approach is shown in Figure 1. First, we cultured nine cancer cell lines, including MCF7, T47D, CAMA1, ZR-75-1, HCC1428, MDA-MB-134, BT483, LY2 and MDA-MB-175 in either 0.2% DMSO (control) or a combination of 0.5 nM everolimus + 25 µM exemestane. The treatment concentration for the experiment was determined based on the dose-response curves of the nine cell lines (Supplementary Figure S1; Supplementary Table S1). After 6 h of treatment, total RNA was extracted from each pair of untreated and treated cell lines and sequenced at a target read depth of 20 M reads. We then filtered the pre-processed gene expression (RSEM) from each cell line to retain the most informative genes by removing low
expression and low variance genes. The expression levels were quantile normalized, followed by feature selection, and fitting a Bayesian binary regression model with treatment status as the outcome (Figure 1A). Concurrently, we obtained gene expression data from pre-treatment biopsies of 23 ER+ breast cancers that received neoadjuvant everolimus for about 2 weeks (Sabine et al., 2010). This trial reported clinical response as a change in Ki67 staining percentage at the end of 11–14 days of treatment, with patients showing more than a 10% decrease in Ki67 staining classified as responders. We then implemented a LOOCV framework that used two sets of features: 1. A set of signature genes from used in the Bayesian binary regression model of the cell lines treated with everolimus and exemestane and 2. A set of features that were selected using FCBF. This integrated set of features was used to train a random forest classifier within each fold of the LOOCV (Figure 1B).

Transcriptomic signature of *in vitro* everolimus response

We created an *in vitro* everolimus response signature using RNA-seq profile of the nine ER+ breast cancer cells, with the treatment status (DMSO vs. everolimus plus exemestane) as the outcome variable. Starting with a matrix of filtered gene expression data across cell lines, we first defined the signature set by selecting genes using Pearson correlation that best differentiated the cell lines based on treatment status (Figure 2A). A Bayesian binary regression model was then fit

![Diagram of integrative approach for mTOR inhibitor biomarker development](image-url)
on the first two principal components of the signature gene expression matrix to classify the cells. This model was sampled using a Markov chain Monte Carlo algorithm to obtain posterior probabilities and 95% confidence intervals (Figure 2B). A probability closer to 1 indicated that the signature genes were active in cells treated with everolimus. As shown in Figure 2B, the signature could clearly distinguish cell lines based on treatment status.

Further examination of the signature genes revealed key biological processes and pathways activated or inactivated in the cell lines post treatment. Enrichment analysis for GO:BP, KEGG and REACTOME terms in the genes expressed at higher levels in cells treated with everolimus revealed activation of pathways related to cell death and apoptosis (Figure 3A; Supplementary Table S2). For example, some of the key enriched pathways included response to oxidative stress, regulation of apoptosis, ferroptosis and pexophagy, which are well-known consequences of mTOR inhibition in vitro. On the other hand, genes that were downregulated were enriched in terms associated with translation and cell proliferation (Figure 3B; Supplementary Table S3). Again, this agreed with the expectation that mTOR inhibition would lead to reduced protein turnover and proliferation rates.

### Predicting clinical response using integrative model

A clinical study of ER+ breast cancers evaluated everolimus response by measuring percentage Ki67 staining change over the course of treatment of 2 weeks (Sabine et al., 2010). This clinical trial reported response data from 23 pre-treatment biopsies and 21 post-treatment biopsies. We used the pre-treatment gene
expression data to develop a biomarker that can predict response to everolimus treatment. This analysis was performed within an LOOCV framework, where each iteration of the cross validation involved selecting relevant features associated with treatment response in the training split, integrating the selected features with the in vitro gene signature, and training and validation of a random forest model. We used FCBF algorithm to select the features associated with treatment response. This algorithm utilized symmetrical uncertainty, an information theory derived concept that selected genes with high correlation with the outcome but low correlation with other variables. The genes selected with FCBF were integrated with the in vitro signature to train and evaluate the random forest model. LOOCV analysis showed that the predicted probabilities of response based on pre-treatment gene

![FIGURE 3](image)

Enrichment analysis of in vitro gene signature. (A,B) The dotplots show significance of the enrichment terms from GO:BP, KEGG and REACTOME signatures, with Y-axis showing $-\log_{10}$ of the FDR-adjusted $p$-value from the enrichment test. Key significant terms enriched in genes that were (A) expressed at higher levels in the treated cells or (B) expressed at higher cells in the untreated cells are annotated in the table below. The term size indicated number of genes in the original signature, while the color code indicates strength of evidence associated with the term. Terms supported by experimental evidence are shown in orange.
expression data agreed with the actual clinical outcomes, as reported by the clinical trial (Figure 4A). Similarly, the predicted probabilities of non-response agreed with the reported clinical response (Figure 4B). Overall, the random forest model fit on the complete clinical dataset of 23 pre-treatment tumor samples was highly accurate, with consistently high accuracies (>0.9) achieved in the LOOCV analyses for tuning the hyperparameters of the random forest model fit on the full dataset (Figure 4C).

Identifying potential candidates for everolimus treatment

Given the high prediction accuracy of the model in LOOCV analyses, we applied the random forest model trained on the full clinical dataset of 23 pre-treatment samples to predict mTOR inhibitor response in the METABRIC cohort of ER+/HER2- tumors (Curtis et al., 2012). This cohort included 833 breast cancer patients that
had received endocrine therapy and were either alive at study completion or died due to the disease. We had previously developed a biomarker model to predict patients with high risk of death on endocrine therapy in this cohort. This model, called ENDORSE, could successfully stratify patients based on predicted endocrine resistance. We had also noted that the patients with ENDORSE risks showed activation of the mTOR signaling pathway. Therefore, we compared the predicted probabilities of mTOR inhibitor response with the ENDORSE classes in the METABRIC cohort. Here, we found that the predicted mTOR response were significantly higher in medium and high-risk groups than the low-risk groups (Figure 5A). Moreover, a large proportion of the high-risk tumors (>40%) showed a high probability of mTOR inhibitor response (>0.75) compared to medium-risk (15%) or low-risk tumors (10%). We further investigated the biological signals enriched in the tumors predicted to be responsive to mTOR inhibitor treatment or (C) expressed at higher levels in the tumors non-responsive to mTOR inhibitor treatment are annotated in the table below. The term size indicated number of genes in the original signature, while the color code indicates strength of evidence associated with the term. Terms supported by weak evidence are shown in blue while experimentally derived signatures are shown in orange.
smoothened signaling pathways (Figure 5C; Supplementary Table S5). These suggested the tumors predicted to be non-responsive to mTOR inhibitors were still largely dependent on estrogen signaling or bypassed mTOR signaling via the smoothened pathway for growth and proliferation.

**Discussion**

The use of mTOR inhibitors such as everolimus has shown promising results in improving outcomes of ER+/HER2- breast cancer patients (Ellard et al., 2009; Baselga et al., 2012; Andre et al., 2014; Piccart et al., 2014). However, there are several treatment options available for progressive and advanced ER+ breast cancers, which include drugs that target the PI3K and mTOR signaling pathways. While the presence of activating mutations on the PIK3CA gene guide the use of PI3K and mTOR inhibitors. The challenge of using mTOR inhibitors like everolimus is completely based on patient and provider choice. Therefore, our goal was to systematically develop a new biomarker that may be useful in predicting clinical outcomes for mTOR inhibitors. We have previously developed a prognostic model for endocrine resistance in breast cancer patients using the tumor baseline transcriptomic data (Nath et al., 2022). Here, we extended our approaches to develop a novel machine learning biomarker for everolimus response.

To date, only one clinical trial with any mTOR inhibitor has reported genomic information from breast cancer patients before and after treatment (Sabine et al., 2010). This trial was of limited size of only 23 pre-treatment samples, which made it challenging to train and develop an effective biomarker model. We addressed this issue by first identifying which genes are expressed in response to everolimus in a well-controlled *in vitro* environment. Such approaches have been extensively used to generate gene expression signatures by directly manipulating the expression of genes or using chemical perturbations *in vitro*. For example, the curated and oncogenic signature collection in the molecular signatures database contains over 3000 such signatures generated using genetic or chemical perturbations (Liberzon et al., 2011) that are frequently used in prognostic and drug response signatures (Sonachalam et al., 2012; Tan et al., 2019; Kong et al., 2020; Zeng et al., 2022).

As the *in vitro* environment is less affected by the inter-sample variances typically observed in animal and patient-derived data, our approach allowed us to pick genes with high confidence that show a significant change upon everolimus treatment and are likely good candidate features for a machine learning biomarker model (Figure 2). These genes were sensible and associated with expected biological phenomenon (Figure 3). We then implemented an approach that leveraged pre-treatment tumor transcriptomes and clinical outcomes data from the 23 patients combined with the *in vitro* signature. This integrated model was highly accurate in predicting clinical everolimus response in the LOOCV analyses of the patient data (Figure 4).

We further applied the biomarker to predict mTOR inhibitor response in an independent cohort of ER+/HER2- breast cancer patients from the METABRIC study (Curtis et al., 2012). We obtained gene expression and overall survival data from 833 patients. These patients had received only endocrine therapy and were classified using a prognostic model that predicted risk of death on endocrine therapy (Nath et al., 2022). We had previously found that the METABRIC patients with high risk of death on endocrine therapy showed elevated pathway activity of PI3K/AKT/mTOR signaling pathway (Nath et al., 2022). By applying our biomarker, we found that indeed a vast proportion of the predicted mTOR responsive patients were those in the high risk group (Figure 5). Activation of mTOR signaling is a well-documented phenomenon associated with endocrine resistance and poor prognosis of ER+ breast cancer patients (Ciucules, Gil, 2014; Paplomata and O’Regan, 2014; Dong et al., 2021; Nunnery and Mayer, 2020). Thus, our novel biomarker could be useful in identifying the patients that are most likely to benefit from mTOR inhibitor treatment.

Another interesting aspect of our study were the biological signatures and pathways activated *in vitro* upon everolimus treatment and the ones enriched in patients predicted to be responsive. The *in vitro* signature largely showed enrichment of expected biological pathways, including cellular oxidative stress (Piao et al., 2014), autophagy (Crazzolara et al., 2009) and apoptosis (Tai et al., 2017). In comparison, the patient data showed a large proportion of immune activation pathways as the most significant signatures. mTOR signaling is well-known to play an important role in directing adaptive immune response by receiving microenvironmental signals and activating T-cells and dendritic cells (Delgoffe and Powell, 2009). In the tumor microenvironment, mTOR signaling regulates the activity of macrophages and T-cells through inflammatory factors like IL-10, TGF-beta, and membrane bound CTLA-4 and PD-1 (Kim et al., 2017). This has been linked with a shift in balance from an anti-tumor to a pro-tumor immune microenvironment by reducing the proportion of anti-tumor CD8+ T-cells and increasing the proportion of Treg and tumor-associated M2 macrophages (Kim et al., 2017; Maft et al., 2021). Thus, the enrichment of these immune activation-related terms in the patient data captures a known effect of elevated mTOR pathway activity and supports the biomarker-driven classification of the patients as likely responders to mTOR inhibition. We also observed an enrichment of smoothened receptor pathway signatures in the mTOR-resistant tumor. As a major component of the hedgehog signaling pathway, both the canonical and non-canonical activation of the smoothened pathway has been linked with stem-cell like traits, invasiveness and metastatic progression of breast cancers (Jeng et al., 2020). Consequently, multiple interventions
targeting the hedgehog and smoothened signaling pathway are currently being evaluated in breast cancer (Bhateja et al., 2019).

Key limitations of this study are lack of a large-scale training dataset and an additional independent validation dataset for the biomarker model. The clinical training data used in the study consisted of only 23 pre-treatment samples, with a large number of potential predictive features. We attempted to mitigate this challenge by systematically reducing the number of predictive features using the in vitro signature and selecting a limited number of empirical features from the clinical datasets for model construction. Furthermore, we performed the model development and validation in a LOOCV framework, where the empirical features from the clinical dataset were only picked from the training split. The model was then applied to predict outcome in the left-out test sample. This approach helped in diminishing problems associated with overfitting models to the data and overestimating model accuracies. Nevertheless, clinical translation of the biomarker will benefit greatly from additional validation and refinement using prospective biopsies or through retrospective analyses of banked samples.

Given that patients progressing on endocrine therapy have multiple treatment options, including aromatase inhibitors, chemotherapy, PI3K inhibition or mTOR blockage, development of biomarkers to guide therapy selection of these patients can help ensure they are treated with the most effective drug regimen. This study uses both experimental and patient-based data to develop a biomarker for response to everolimus, and to understand the signaling underlying inhibition of mTOR signaling in ER+ breast cancer.

Data availability statement

The neoadjuvant everolimus clinical trial dataset used in this study can be found in the NCBI GEO repository under the accession GSE119262 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119262). The METABRIC dataset can be obtained from the cBioPortal for cancer genomics (https://www.cbioportal.org/study/summary?id=brca_metabric). Scripts associated with this manuscript are available at https://github.com/aritronath/Everolimus_MLB. The GenePattern BinReg module, results, and the RNA-seq input data for the nine ER+ breast cancer cell lines analyzed in this study are also available in this GitHub repository under “releases”. Genes in the final integrative signature are provided in Supplementary Table 6.

Author contributions

AN: Conceptualization; Data curation; Software; Formal analysis; Validation; Investigation; Visualization; Methodology; Writing—original draft; Writing—review and editing. JC: Data curation; Software; Formal analysis; Validation; Investigation. AB: Conceptualization; Resources; Supervision; Funding acquisition; Investigation; Methodology; Project administration; Writing—review and editing.

Funding

Research reported in this publication was supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under award number U54CA209978 awarded to AB, JC, and a pilot grant awarded through U54CA209978 to AN.

Acknowledgments

The authors would like to acknowledge the work provided by the Leadership and Staff of the CoH Center for Informatics most notably Research Informatics, and the utilization of the POSEIDON data exploration, visualization, and analysis platform including the Honest Broker process. Figure 1 was created with BioRender.com.

Conflict of interest

AN and AB are listed co-inventors on a patent application (filed, pending) covering the mTOR inhibitor response gene signature described in this manuscript.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2022.981962/full#supplementary-material
References

Anders, S., Pyl, P. T., and Huber, W. (2015). Htseq--A Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169. doi:10.1093/bioinformatics/btu103

Andre, F., O’regan, R., O’zgur, M., Toi, M., Xu, B., Jerusalem, G., et al. (2014). Everolimus for women with trastuzumab-resistant, her2-positive, advanced breast cancer (boler3-3): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. Oncol. 15, 580–591. doi:10.1016/s1470-2045(14)70138-x

Baselga, J., Campone, M., Piccart, M., Burris, H. A., 3rd, Rugo, H. S., Sahnoud, T., et al. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529. doi:10.1056/NEJMoa1110653

Bhatiya, P., Cherman, M., Majumder, S., and Ramaswamy, B. (2019). The hedgesignaling pathway: A viable target in breast cancer? Cancers 11, E1126. doi:10.3390/cancers11011126

Bolger, A. M., Lohse, M., and Usadel, B. (2014). Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120. doi:10.1093/bioinformatics/btu170

Chang, J. T., Gata, M. L., Lucas, J. E., Barry, W. T., Vaughn, P., and Nevins, J. R. (2011). Signature: A workbench for gene expression signature analysis. Bioinforma. 27, 4536–4541. doi:10.1093/bioinformatics/btq817

Clarke, R., Tyson, J. J., and Dixon, J. M. (2015). Endocrine resistance in breast cancer--an overview and update. Mol. Cell. Endocrinol. 418, 220–234. doi:10.1016/j.mce.2015.09.035

Crazzolara, K., Bradstock, K. F., and Bendall, L. J. (2009). Rad001 (everolimus) induces autophagy in acute lymphoblastic leukaemia. Autophagy 5, 727–728. doi:10.4161/auto.5.5.8507

Curtis, C., Shah, S. P., Chin, S. F., Turashvili, G., Rueda, O. M., Dunning, M. J., et al. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352. doi:10.1038/nature10983

Delgoffe, G. M., and Powell, J. D. (2009). Mtor: Taking cues from the immune microenvironment. Immunology 127, 459–465. doi:10.1111/j.1365-2664.2009.03125.x

Dobin, A., Davis, C. A., Schlesinger, F., Wrenn, J., Zaleski, C., Jha, S., et al. (2013). Star: Ultrafast universal rna-seq aligner. Bioinformatics 29, 12–21. doi:10.1093/bioinformatics/btt628

Dong, C., Wu, J., Chen, Y., Nie, J., and Chen, C. (2021). Activation of pi3k/akt/mtor pathway causes drug resistance in breast cancer. Front. Pharmacol. 12, 628690. doi:10.3389/fphar.2021.628690

Everolimus for women with trastuzumab-resistant, her2-positive, advanced breast cancer (boler3-3): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. Oncol. 15, 580–591. doi:10.1016/s1470-2045(14)70138-x

Et al. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352. doi:10.1038/nature10983

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from bolero-2. Ann. Oncol. 25, 2357–2362. doi:10.1093/annonc/mdu456

Kong, J., Lee, H., Kim, D., Han, S. K., Ha, D., Shin, K., et al. (2020). Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug sensitivity in patients. Nat. Commun. 11, 5485. doi:10.1038/s41467-020-19313-8

Kuhn, M. (2021). Caret: Classification and regression training. Version 6.0-88 Ed R Package.

Li, B., and Dewey, C. N. (2011). Rsem: Accurate transcript quantification from rna-seq data with or without a reference genome. BMC Bioinforma. 12, 323. doi:10.1186/1471-2105-12-323

Liaw, A., and Wiener, M. (2002). Classification and regression by randomforest. R News 2 (3), 18–22.

Liberson, A., Subramanian, A., Pinchback, R., Thorvaldsdottir, H., Tamayo, P., and Mesirov, J. P. (2011). Molecular signatures database (msigdb) 3.0. Bioinformatics 27, 1739–1740. doi:10.1093/bioinformatics/btr260

Lubiana, T., and Nakaya, H. (2021). Fclib: Fast correlation based filter for feature selection. R Package Version 2.0.0

Mafi, S., Mansoori, B., Tash, S., Sadeghi, H., Abbasi, R., Cho, W. C., et al. (2021). Mtor-mediated regulation of immune responses in cancer and tumor microenvironment. Front. Immunol. 12, 774103. doi:10.3389/fimmu.2021.774103

Musgrove, E. A., and Sutherland, R. L. (2009). Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631–643. doi:10.1038/nrc26713

Nath, A., Cohen, A. L., and Bild, A. H. (2022). Endorse: A prognostic model for everolimus in patients with hr-positive, her2-negative, pik3ca-mutated, advanced or metastatic breast cancer. Cancer Treat. Rev. 48, 1–11. doi:10.1016/j.ctrv.2021.101874

Nath, A., Lau, E. Y. T., Lee, A. M., Geeleher, P., Cho, W. C., Huang, R. S. et al. (2021). Fda approval summary: Alpelisib plus fulvestrant for patients with hr-negative, her2-negative, advanced or metastatic breast cancer. Cancer Treat. Rev. 27, 453–461. doi:10.1016/j.ctrv.2021.101874

Nath, A., O’Regan, R., and D’Souza, E. (2014). Targeting the pi3k/akt/mtor pathway in estrogen-receptor-positive breast cancers. Mol. Syst. Biol. 18, E0155. doi:10.15252/msb.202110558

Nath, A., Lee, Y. T., Lee, A. M., Gleeheer, P., Cho, W. C. S., and Huang, R. S. (2019). Discovering long noncoding rna predictors of anticaner drug sensitivity beyond protein-coding genes. Proc. Natl. Acad. Sci. U. S. A. 116, 22020–22029. doi:10.1073/pnas.1909989116

Nunnery, S. E., and Mayer, I. A. (2020). Targeting the pi3k/akt/mtor pathway in hormone-sensitive breast cancer. Drugs 80, 1685–1697. doi:10.1007/s40265-020-01394-w

Osborne, C. K., and Schiff, R. (2011). Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233–247. doi:10.1146/annurev-med-070909-182917

Papamata, E., and O’Regan, R. (2014). The pi3k/akt/mtor pathway in breast cancer: Targets, trials and biomarkers. Ther. Adv. Med. Oncol. 6, 154–166. doi:10.1177/1758824114530023

Patel, H. K., and Bihani, T. (2018). Selective estrogen receptor modulators (serms) and selective estrogen receptor degraders (serds) in cancer treatment. Pharmacol. Ther. 186, 1–24. doi:10.1016/j.pharmthera.2017.12.012

Piao, S. G., Lim, S. W., Doh, K. C., Jin, L., Heo, S. B., Zheng, Y. F., et al. (2014). Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. Transplantation 98, 22–28. doi:10.1097/TP.0000000000001461

Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., et al. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from bolero-2. Ann. Oncol. 25, 2357–2362. doi:10.1093/annonc/mdu456

– an R package for gene list functional enrichment analysis and namespace conversion. Toolset G2Profiler. F1000res, 9.

Frontiers in Molecular Biosciences frontiersin.org
Sonachalam, M., Shen, J., Huang, H., and Wu, X. (2012). Systems biology approach to identify gene network signatures for colorectal cancer. *Front. Genet.* 3, 80. doi:10.3389/fgene.2012.00080

Tai, S., Xu, L., Xu, M., Zhang, L., Zhang, Y., Zhang, K., et al. (2017). Combination of arsenic trioxide and everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells. *Oncotarget* 8, 11206–11218. doi:10.18632/oncotarget.14493

Tan, T. Z., Ye, J., Yee, C. V., Lim, D., Ngoi, N. Y. L., Tan, D. S. P., et al. (2019). Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. *Ebiomedicine* 50, 203–210. doi:10.1016/j.ebiom.2019.11.017

West, M., Blanchette, C., Dressman, H., Huang, E., Ishida, S., Spang, R., et al. (2001). Predicting the clinical status of human breast cancer by using gene expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* 98, 11462–11467. doi:10.1073/pnas.201162998

Zeng, A. G. X., Bansal, S., Jin, L., Mitchell, A., Chen, W. C., Abbas, H. A., et al. (2022). A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. *Nat. Med.* 28, 1212–1223. doi:10.1038/s41591-022-01819-x